Abstract Library

#2876 Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs)

Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,

Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,

#2168 Phase II Trial of Cabozantinib in Patients with Carcinoid and Pancreatic Neuroendocrine Tumors

Introduction: Activation of VEGFR2 and MET is implicated in driving growth of NET. Cabozantinib inhibits VEGFR2, MET, AXL, RET.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Chan J, Faris J, Murphy J, Blaszkowsky L, McCleary N,

Keywords: cabozantinib, pancreatic neuroendocrine tumor, carcinoid, phase II,

#2011 Expression and Clinical Significance of Vascular Endothelial Growth Factor Receptor 3 (VEGFR3) and Phospho-VEGFR3 in Gastroenteropancreatic Neuroendocrine Neoplasms

Introduction: The expression of vascular endothelial growth factor Receptor 3 (VEGFR3) and phospho-VEGFR3 (pVEGFR3) in gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and their clinical significance are still unknown.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Zhang Y

Authors: Zhang Y, Chen L, Lin Y, Chen M, Chen J,

Keywords: gastroenteropancreatic neuroendocrine neoplasms, vascular endothelial growth factor Receptor 3, expression, clinical significance,

#1772 Expression of Truncated Functional Subtype 5 Somatostatin Receptor Variant (sst5TMD4) in GEP-NETs and Association with Relevant Pathways Involved in NET Tumorigenesis

Introduction: Sst5TMD4, which is derived from a non-canonical splicing process of sst5 receptor, is overexpressed in several endocrine tumors and associated with a worse prognosis.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Diaz Perez A, Martínez-Fuentes A, García-Carbonero R, Luque R, Jimenez-Fonseca P,

Keywords: somatostatin receptor, neuroendocrine tumors,

#1374 The Usefulness of Assessment the Serum Concentrations of Vascular Endothelial Growth Factor (VEGF) and Its Soluble Receptor Type 2 (VEGFR2) in Patients with Neuroendocrine Neoplasm (NEN)

Introduction: Angiogenesis plays an important role in tumour growth and disease progression. VEGF is a angiogenesis-stimulating factor. VEGFR2 has antiangiogenic properties.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Rosiek V, Kos-Kudła B, Zemczak A,

Keywords: neuroendocrine neoplasms, VEGF, VEGFR2,